SightfileU.S. market data from official filings

Companies › DMAC

DIAMEDICA THERAPEUTICS INC (DMAC)

Institutional ownership, SEC filings and insider activity

Sector: Healthcare & Pharma · SEC CIK 0001401040 · EDGAR filings · Updated 2026-06-03

DIAMEDICA THERAPEUTICS INC (DMAC) has reported institutional ownership of 21.7%, with 98 institutional managers holding positions valued at $79.2M per the latest 13F reporting period. SEC filings include an active substantial-doubt (going concern) disclosure per the filings.

Institutional ownership
21.7%
Institutional managers
98
Reported 13F value
$79.2M
Insider activity
24 trans.
$30.4M net buying
Data flags
1 active
from SEC filings

Latest updates

Institutional ownership overview

According to SEC 13F filings tracked by Sightfile, DIAMEDICA THERAPEUTICS INC has 98 institutional holders and institutional ownership of 21.7%.

Insider activity

Insiders reported 24 transactions (19 buys, 0 sells) across 13 reporting insiders, with a net reported value of $30.4M.

Data flags from SEC filings

Active substantial-doubt (going concern) disclosure per the filings, most recently filed 2021-08-11 (recurring since 2021-08-11) — source filing. The authoritative details are those stated in the filing itself.

Related companies

EQUILLIUM INC (EQ) · GOSSAMER BIO INC (GOSS) · ADLAI NORTYE LTD (ANL) · STEREOTAXIS INC (STXS) · PROMIS NEUROSCIENCES INC (PMN) · APYX MEDICAL CORPORATION (APYX)

See full history, cross-references and alerts on Sightfile
Sightfile provides information only — not investment advice, recommendations, or an assessment of any security. Data is derived from official public sources (SEC EDGAR and U.S. government agencies), may contain errors or delays, and should be verified against the source filing before relying on it.
Data sources: SEC EDGAR (filings, 13F, FTD), aggregated by Sightfile. Page updated 2026-06-03.